Another study consisting of 323 breast cancer patients receiving anthracyclines and/or trastuzumab found that changes in NT-proBNP were associated with changes in LVEF and cancer therapy-related cardiac dysfunction [23], confirming smaller studies that illustrated persistent elevations in BNP portend worse prognosis [11,12]. The gene discussed is NPPB; the disease is breast carcinoma.